You have read all your free articles, to continue reading subscribe to read the rest of this content.
Elicera Therapeutics has filed a patent application to protect the development of its drug candidate ELC-201. ELC-201 is the second oncolytic virus in Elicera Therapeutic's product portfolio. It is based on an adenovirus that has been genetically modified in a way that makes the treatment applicaAlready a subscriber Login You…
Zelluna Immunotherapy has announced an investment from Takeda Ventures, the strategic investing arm of Takeda. TVI investment joins Zelluna’s latest financing round, the company states. “We are delighted to have TVI as a strategic investor in Zelluna. The company has developed very well frAlready a subscriber Login You have read…
Cantargia AB’s patent application for IL1RAP as target molecule for antibody-based therapies and diagnostics of solid tumours has been approved by the Japan Patent Office (JPO). The patent approval (patent no. 5940093) refers to the company’s method of using IL1RAP as target molecule for trAlready a subscriber Login You have read all…
The issued patent covers the Dosage Manager device platform developed by OnDosis for dosing of oral solid medicines in the form of pellets. The issued patent is the first relating to OnDosis device and its core design and functionality, and the company expects further patents to follow in due couAlready…
